It also inhibits p‐STAT3 levels following treatment in PDAC cells (Figure 2) as well as inhibition of direct STAT3 targets including survivin, c‐Myc and Nanog in prostate cancer cells.16 This evidence concerns the gene BIRC5 and prostate carcinoma.